- Home
- BCAB vs APM Comparison
BCAB vs APM Comparison
Compare BCAB & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- APM
- Stock Information
- Founded
- BCAB 2007
- APM 2010
- Country
- BCAB United States
- APM United Kingdom
- Employees
- BCAB N/A
- APM N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- APM Health Care
- Exchange
- BCAB Nasdaq
- APM Nasdaq
- Market Cap
- BCAB 21.6M
- APM 18.9M
- IPO Year
- BCAB 2020
- APM 2018
- Fundamental
- Price
- BCAB $0.45
- APM $2.25
- Analyst Decision
- BCAB Hold
- APM
- Analyst Count
- BCAB 3
- APM 0
- Target Price
- BCAB $1.00
- APM N/A
- AVG Volume (30 Days)
- BCAB 561.4K
- APM 20.3M
- Earning Date
- BCAB 08-07-2025
- APM 04-30-2025
- Dividend Yield
- BCAB N/A
- APM N/A
- EPS Growth
- BCAB N/A
- APM N/A
- EPS
- BCAB N/A
- APM N/A
- Revenue
- BCAB $11,000,000.00
- APM N/A
- Revenue This Year
- BCAB N/A
- APM N/A
- Revenue Next Year
- BCAB N/A
- APM N/A
- P/E Ratio
- BCAB N/A
- APM N/A
- Revenue Growth
- BCAB N/A
- APM N/A
- 52 Week Low
- BCAB $0.24
- APM $0.46
- 52 Week High
- BCAB $2.53
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- BCAB 65.33
- APM 54.95
- Support Level
- BCAB $0.35
- APM $2.17
- Resistance Level
- BCAB $0.38
- APM $2.65
- Average True Range (ATR)
- BCAB 0.03
- APM 0.33
- MACD
- BCAB 0.01
- APM 0.09
- Stochastic Oscillator
- BCAB 90.66
- APM 31.90
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.